GENENTECH, INC.
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1976-01-01
- Employees
- 11.1K
- Market Cap
- -
- Website
- http://www.gene.com
A Study to Evaluate the Effect of Injection Site on PK of Astegolimab in Healthy Subjects
- First Posted Date
- 2024-06-17
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 78
- Registration Number
- NCT06462118
- Locations
- 🇺🇸
Covance Research Unit - Daytona, Daytona Beach, Florida, United States
🇺🇸Covance Clinical Research Unit, Inc, Madison, Wisconsin, United States
🇺🇸Covance Research Unit - Dallas, Dallas, Texas, United States
A Study of RO7617991 in Patients With Locally Advanced or Metastatic MAGE-A4-Positive Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2024-04-18
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 210
- Registration Number
- NCT06372574
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vixarelimab in Participants With Moderate to Severe Ulcerative Colitis (UC)
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 210
- Registration Number
- NCT06137183
- Locations
- 🇺🇸
Sylvester Comprehensive Cancer Center, Miami, Florida, United States
🇩🇪Universitaetsklinikum Halle (Saale); Universitatsklinik und Poliklinik fur Innere Medizin I, Halle, Germany
🇵🇱PlanetMed, Wroc?aw, Poland
A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Patients With Unresectable Hepatocellular Carcinoma and Child-Pugh B7 and B8 Cirrhosis
- First Posted Date
- 2023-10-24
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT06096779
- Locations
- 🇺🇸
University of Southern California; Oncology/Hematology, Newport Beach, California, United States
🇺🇸Veterans Affairs Pittsburgh Healthcare System - NAVREF - PPDS, Pittsburgh, Pennsylvania, United States
🇺🇸Kelsey Research Foundation, Houston, Texas, United States
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2023-09-11
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 250
- Registration Number
- NCT06031441
- Locations
- 🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada
🇺🇸SCRI Oncology Partners, Nashville, Tennessee, United States
🇨🇦British Columbia Cancer Agency - 600 10th Ave W, Vancouver, British Columbia, Canada
A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC
- Conditions
- Interventions
- First Posted Date
- 2023-08-01
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 260
- Registration Number
- NCT05968326
- Locations
- 🇪🇸
Centro Integral Oncológico Clara Campal Ensayos Clínicos START, Madrid, Spain
🇬🇧Addenbrookes Hospital; Cambridge Cancer Trials Centre, S4 Box 279, Cambridge, United Kingdom
🇺🇸USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Either Osimertinib in Participants With Unresectable, Locally Advanced, or Metastatic Non-Small Cell Lung Cancer, or With Cetuximab in Participants With Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-07-20
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 172
- Registration Number
- NCT05954871
- Locations
- 🇺🇸
Yale Cancer Center, New Haven, Connecticut, United States
🇺🇸Christiana Care Health System, Newark, Delaware, United States
🇺🇸SCRI Oncology Partners, Nashville, Tennessee, United States
A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)
- Conditions
- Interventions
- First Posted Date
- 2023-07-03
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT05927571
- Locations
- 🇮🇱
Tel Aviv Sourasky Medical Center PPDS, Tel Aviv-Yafo, Israel
🇮🇱Sheba Medical Center - PPDS, Ramat Gan, Israel
🇦🇺The Alfred Hospital, Prahan, Victoria, Australia
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-Care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors
- First Posted Date
- 2023-05-19
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 102
- Registration Number
- NCT05867121
- Locations
- 🇺🇸
UCLA University of California Los Angeles, Los Angeles, California, United States
🇺🇸Yale School of Medicine, New Haven, Connecticut, United States
🇺🇸Thomas Jefferson University, Philadelphia, Pennsylvania, United States
A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-04-05
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 160
- Registration Number
- NCT05800665
- Locations
- 🇦🇺
Macquarie University Hospital, Sydney, New South Whales, Australia
🇨🇦British Columbia Cancer Agency, Vancouver, British Columbia, Canada
🇫🇷Centre Léon Bérard, Lyon, Auvergne-Rhône-Alpes, France